Praxis Precision Medicines (PRAX) Competitors $58.01 +0.92 (+1.61%) Closing price 04:00 PM EasternExtended Trading$57.96 -0.04 (-0.08%) As of 07:33 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock PRAX vs. KRYS, AKRO, RNA, PTCT, ACLX, MRUS, ZLAB, SRRK, ACAD, and VKTXShould you be buying Praxis Precision Medicines stock or one of its competitors? The main competitors of Praxis Precision Medicines include Krystal Biotech (KRYS), Akero Therapeutics (AKRO), Avidity Biosciences (RNA), PTC Therapeutics (PTCT), Arcellx (ACLX), Merus (MRUS), Zai Lab (ZLAB), Scholar Rock (SRRK), ACADIA Pharmaceuticals (ACAD), and Viking Therapeutics (VKTX). These companies are all part of the "pharmaceutical products" industry. Praxis Precision Medicines vs. Its Competitors Krystal Biotech Akero Therapeutics Avidity Biosciences PTC Therapeutics Arcellx Merus Zai Lab Scholar Rock ACADIA Pharmaceuticals Viking Therapeutics Praxis Precision Medicines (NASDAQ:PRAX) and Krystal Biotech (NASDAQ:KRYS) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their media sentiment, institutional ownership, analyst recommendations, dividends, earnings, profitability, risk and valuation. Do insiders & institutionals believe in PRAX or KRYS? 67.8% of Praxis Precision Medicines shares are held by institutional investors. Comparatively, 86.3% of Krystal Biotech shares are held by institutional investors. 2.7% of Praxis Precision Medicines shares are held by insiders. Comparatively, 13.7% of Krystal Biotech shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. Which has better earnings & valuation, PRAX or KRYS? Krystal Biotech has higher revenue and earnings than Praxis Precision Medicines. Praxis Precision Medicines is trading at a lower price-to-earnings ratio than Krystal Biotech, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPraxis Precision Medicines$8.55M138.21-$182.82M-$10.72-5.41Krystal Biotech$290.52M14.92$89.16M$4.1636.06 Which has more volatility & risk, PRAX or KRYS? Praxis Precision Medicines has a beta of 2.6, suggesting that its share price is 160% more volatile than the S&P 500. Comparatively, Krystal Biotech has a beta of 0.67, suggesting that its share price is 33% less volatile than the S&P 500. Is PRAX or KRYS more profitable? Krystal Biotech has a net margin of 37.17% compared to Praxis Precision Medicines' net margin of -2,137.48%. Krystal Biotech's return on equity of 14.64% beat Praxis Precision Medicines' return on equity.Company Net Margins Return on Equity Return on Assets Praxis Precision Medicines-2,137.48% -50.42% -46.74% Krystal Biotech 37.17%14.64%13.28% Do analysts recommend PRAX or KRYS? Praxis Precision Medicines currently has a consensus price target of $94.11, suggesting a potential upside of 62.23%. Krystal Biotech has a consensus price target of $211.33, suggesting a potential upside of 40.89%. Given Praxis Precision Medicines' higher probable upside, equities research analysts plainly believe Praxis Precision Medicines is more favorable than Krystal Biotech.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Praxis Precision Medicines 1 Sell rating(s) 0 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 2.78Krystal Biotech 0 Sell rating(s) 1 Hold rating(s) 8 Buy rating(s) 1 Strong Buy rating(s) 3.00 Does the media prefer PRAX or KRYS? In the previous week, Krystal Biotech had 2 more articles in the media than Praxis Precision Medicines. MarketBeat recorded 10 mentions for Krystal Biotech and 8 mentions for Praxis Precision Medicines. Krystal Biotech's average media sentiment score of 0.73 beat Praxis Precision Medicines' score of 0.37 indicating that Krystal Biotech is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Praxis Precision Medicines 1 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Krystal Biotech 5 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SummaryKrystal Biotech beats Praxis Precision Medicines on 13 of the 16 factors compared between the two stocks. Get Praxis Precision Medicines News Delivered to You Automatically Sign up to receive the latest news and ratings for PRAX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding PRAX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PRAX vs. The Competition Export to ExcelMetricPraxis Precision MedicinesMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.16B$3.06B$5.70B$9.48BDividend YieldN/A2.37%4.59%3.99%P/E Ratio-5.4120.7327.9019.95Price / Sales138.21321.12442.19102.72Price / CashN/A43.2336.5558.97Price / Book2.438.308.635.90Net Income-$182.82M-$55.19M$3.24B$258.42M7 Day Performance5.59%5.07%3.22%1.94%1 Month Performance31.96%17.61%10.72%12.02%1 Year Performance1.58%7.03%34.94%20.81% Praxis Precision Medicines Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PRAXPraxis Precision Medicines2.6169 of 5 stars$58.01+1.6%$94.11+62.2%-1.9%$1.16B$8.55M-5.41110KRYSKrystal Biotech4.8809 of 5 stars$150.41+1.5%$213.75+42.1%-26.0%$4.35B$290.52M36.16210Analyst ForecastAKROAkero Therapeutics3.796 of 5 stars$52.73+2.2%$82.50+56.5%+86.5%$4.20BN/A-27.0430Positive NewsRNAAvidity Biosciences2.4518 of 5 stars$33.57+6.7%$66.35+97.7%-26.2%$4.05B$8.93M-11.19190News CoverageHigh Trading VolumePTCTPTC Therapeutics4.4237 of 5 stars$49.46+1.9%$65.00+31.4%+40.3%$3.92B$806.78M7.601,410Positive NewsACLXArcellx2.6248 of 5 stars$69.92+1.4%$111.23+59.1%+10.8%$3.85B$76.81M-23.3880News CoveragePositive NewsMRUSMerus2.1208 of 5 stars$55.62+2.1%$84.64+52.2%+15.5%$3.85B$36.13M-13.6337Upcoming EarningsZLABZai Lab3.485 of 5 stars$34.28+4.7%$54.28+58.3%+92.7%$3.81B$398.99M-13.771,869Positive NewsGap UpSRRKScholar Rock3.3951 of 5 stars$38.59+3.1%$42.67+10.6%+331.6%$3.66B$33.19M-15.25140Analyst RevisionACADACADIA Pharmaceuticals4.2561 of 5 stars$21.89+4.3%$27.88+27.3%+27.9%$3.66B$957.80M15.98510Positive NewsAnalyst ForecastVKTXViking Therapeutics4.8015 of 5 stars$31.63+1.7%$87.15+175.5%-35.2%$3.55BN/A-27.5020Trending NewsEarnings ReportAnalyst ForecastGap Down Related Companies and Tools Related Companies Krystal Biotech Competitors Akero Therapeutics Competitors Avidity Biosciences Competitors PTC Therapeutics Competitors Arcellx Competitors Merus Competitors Zai Lab Competitors Scholar Rock Competitors ACADIA Pharmaceuticals Competitors Viking Therapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:PRAX) was last updated on 7/24/2025 by MarketBeat.com Staff From Our PartnersElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | SponsoredWhy Elon put $51 million into thisA single U.S. company has started producing a “miracle metal” once locked in research labs. Now? They’re qu...True Market Insiders | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredTreasury Secretary Bessent Is Betting Big on GoldWhen the U.S. Treasury Secretary’s largest personal investment is gold — that’s a signal. Now a veteran gol...Golden Portfolio | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredThink you missed gold’s boom? Think againIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | SponsoredCritical AI announcement set to ignite AI 2.0 I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredA grave, grave error.I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Praxis Precision Medicines, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Praxis Precision Medicines With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free PRAX Stock Alerts